Filana Therapeutics Q2 2026 net loss $8.6M; cash $82.7M; clinical hold on TSC trial continues

FILANA THERAPEUTICS, INC.

Net loss of $8.6M ($0.18 per share) vs $44.2M ($0.92) in Q2 2025; improvement due to no repeat of $31.25M litigation loss.
Cash and equivalents $82.7M at June 30, 2026, down from $95.5M at Dec 31, 2025; no debt.
R&D expenses $3.3M (down 35% YoY) as Alzheimer's program phased out; G&A $6.1M (down 85% YoY).
Paid $31.25M into escrow on July 23, 2026 for securities litigation settlement; cash restricted pending court approval.
Unrestricted cash at year-end 2026 expected $36-40M; second-half 2026 operating cash use $11-15M plus litigation funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.